We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+8.8%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$5.06B
AUM Growth
+$476M
Cap. Flow
+$367M
Cap. Flow %
7.25%
Top 10 Hldgs %
27.38%
Holding
165
New
14
Increased
67
Reduced
10
Closed
9

Top Buys

Rank Stock Value
1
AGL icon
Agilon Health
AGL
+$245M
2
LENZ
LENZ Therapeutics
LENZ
+$53.5M
3
NEUE
NeueHealth
NEUE
+$40.7M
4
VERV
Verve Therapeutics
VERV
+$40M
5
LFST icon
Lifestance Health
LFST
+$39.6M

Top Sells

Rank Stock Value
1
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$100M
2
AZN icon
AstraZeneca
AZN
+$32.3M
3
AVIR icon
Atea Pharmaceuticals
AVIR
+$27.2M
4
INSP icon
Inspire Medical Systems
INSP
+$20.7M
5
UNH icon
UnitedHealth
UNH
+$14M

Sector Composition

Rank Sector Weight
1 Healthcare 94.21%
2 Consumer Staples 1.63%
3 Industrials 0.71%
4 Financials 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
26
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$58.5M 1.16%
625,000
– –
VERV
27
DELISTED
Verve Therapeutics
VERV
$58M 1.15%
+962,826
New +$40M
EAR
28
DELISTED
Eargo, Inc. Common Stock
EAR
$57.9M 1.14%
72,500
+29,916
+70% +$25.1M
TFX icon
29
Teleflex
TFX
$5.98B
$52.2M 1.03%
130,000
– –
MRTX
30
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$51.5M 1.02%
319,085
-4,562
-1% -$732K
ALNY icon
31
Alnylam Pharmaceuticals
ALNY
$29.3B
$50.9M 1.01%
300,000
– –
PRTA icon
32
Prothena Corp
PRTA
$450M
$48.8M 0.97%
950,091
-206,809
-18% -$6.45M
ARVN icon
33
Arvinas
ARVN
$572M
$48.2M 0.95%
626,100
+4,300
+0.7% +$299K
RARE icon
34
Ultragenyx Pharmaceutical
RARE
$2.55B
$44.3M 0.88%
465,000
+15,000
+3% +$1.56M
KRTX
35
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$44.1M 0.87%
386,618
+17,854
+5% +$2.09M
ACHC icon
36
Acadia Healthcare
ACHC
$2.94B
$43.9M 0.87%
700,000
– –
HCAT icon
37
Health Catalyst
HCAT
$128M
$43.6M 0.86%
785,000
– –
LFST icon
38
Lifestance Health
LFST
$4.14B
$41.8M 0.83%
+1,500,000
New +$39.6M
SWAV
39
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$41.7M 0.82%
220,000
– –
NEUE
40
DELISTED
NeueHealth
NEUE
$40.8M 0.81%
+29,688
New +$40.7M
PEN icon
41
Penumbra
PEN
$12.8B
$40.4M 0.8%
147,500
– –
ARDX icon
42
Ardelyx
ARDX
$997M
$39.8M 0.79%
5,248,829
+72,268
+1% +$534K
SGEN
43
DELISTED
Seagen Inc. Common Stock
SGEN
$39.5M 0.78%
250,000
– –
BIIB icon
44
Biogen
BIIB
$30.7B
$39.3M 0.78%
113,500
– –
CVET
45
DELISTED
Covetrus, Inc. Common Stock
CVET
$39.3M 0.78%
1,455,000
+55,000
+4% +$1.54M
EHC icon
46
Encompass Health
EHC
$12.4B
$39M 0.77%
628,500
– –
NVCR icon
47
NovoCure
NVCR
$1.91B
$38.8M 0.77%
175,000
– –
MRSN
48
DELISTED
Mersana Therapeutics
MRSN
$38.6M 0.76%
113,825
+2,820
+3% +$1.07M
ACCD
49
DELISTED
Accolade Inc
ACCD
$36.1M 0.71%
665,000
+40,000
+6% +$1.94M
EVH icon
50
Evolent Health
EVH
$447M
$35.9M 0.71%
1,699,043
+254,043
+18% +$5.09M
1
2
3 4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Rock Springs Capital Management held 165 positions worth $5.06B, up 10% from $4.58B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rock Springs Capital Management deployed $367M of net new capital in Q2 2021, opening 14 new positions and adding to 67 existing holdings. Its largest new stake was Agilon Health: 279,961 shares worth $284M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 94% a quarter earlier, followed by Consumer Staples and Industrials.

On the sell side, the largest reduction was Atea Pharmaceuticals, an estimated $27.2M trimmed.

  • Rock Springs Capital Management's largest Q2 2021 buy was Agilon Health: 279,961 shares worth $284M.
  • Rock Springs Capital Management added most to Eargo, Inc. Common Stock in Q2 2021, an estimated $25.1M increase.
  • Rock Springs Capital Management's biggest Q2 2021 reduction was Atea Pharmaceuticals, cutting an estimated $27.2M.
  • Rock Springs Capital Management fully exited Five Prime Therapeutics, Inc. in Q2 2021, selling an estimated $100M.
  • Rock Springs Capital Management's ten largest holdings make up 27% of its $5.06B portfolio in Q2 2021.
  • Rock Springs Capital Management opened 14 new positions and closed 9 in Q2 2021.
  • Rock Springs Capital Management's portfolio value rose 10% quarter-over-quarter to $5.06B.

Based on Rock Springs Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.